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A B S T R A C T
Background
It is widely claimed that racial and ethnic minorities, especially in the US, are less willing than
non-minority individuals to participate in health research. Yet, there is a paucity of empirical
data to substantiate this claim.
Methods and Findings
We performed a comprehensive literature search to identify all published health research
studies that report consent rates by race or ethnicity. We found 20 health research studies that
reported consent rates by race or ethnicity. These 20 studies reported the enrollment decisions
of over 70,000 individuals for a broad range of research, from interviews to drug treatment to
surgical trials. Eighteen of the twenty studies were single-site studies conducted exclusively in
the US or multi-site studies where the majority of sites (i.e., at least 2/3) were in the US. Of the
remaining two studies, the Concorde study was conducted at 74 sites in the United Kingdom,
Ireland, and France, while the Delta study was conducted at 152 sites in Europe and 23 sites in
Australia and New Zealand. For the three interview or non-intervention studies, African-
Americans had a nonsignificantly lower overall consent rate than non-Hispanic whites (82.2%
versus 83.5%; odds ratio [OR] ¼ 0.92; 95% confidence interval [CI] 0.84–1.02). For these same
three studies, Hispanics had a nonsignificantly higher overall consent rate than non-Hispanic
whites (86.1% versus 83.5%; OR ¼ 1.37; 95% CI 0.94–1.98). For the ten clinical intervention
studies, African-Americans’ overall consent rate was nonsignificantly higher than that of non-
Hispanic whites (45.3% versus 41.8%; OR¼ 1.06; 95% CI 0.78–1.45). For these same ten studies,
Hispanics had a statistically significant higher overall consent rate than non-Hispanic whites
(55.9% versus 41.8%; OR¼ 1.33; 95% CI 1.08–1.65). For the seven surgery trials, which report all
minority groups together, minorities as a group had a nonsignificantly higher overall consent
rate than non-Hispanic whites (65.8% versus 47.8%; OR ¼ 1.26; 95% CI 0.89–1.77). Given the
preponderance of US sites, the vast majority of these individuals from minority groups were
African-Americans or Hispanics from the US.
Conclusions
We found very small differences in the willingness of minorities, most of whom were African-
Americans and Hispanics in the US, to participate in health research compared to non-Hispanic
whites. These findings, based on the research enrollment decisions of over 70,000 individuals,
the vast majority from the US, suggest that racial and ethnic minorities in the US are as willing
as non-Hispanic whites to participate in health research. Hence, efforts to increase minority
participation in health research should focus on ensuring access to health research for all
groups, rather than changing minority attitudes.
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Introduction
To ensure the generalizability of research results, it is
important that all groups participate in health research [1–4].
However, many commentators claim that racial and ethnic
minority groups, especially in the US, are less willing to
participate in health research [5–13]. While the US popula-
tion includes an increasing percentage of individuals from
minority groups, non-Hispanic whites still compose a
majority of the population (Figure 1). It is widely believed
that racial and ethnic minority groups in the US, especially
African-Americans, are less willing than non-Hispanic whites
to participate in health research. Many commentators believe
that this relative unwillingness traces to past abuses,
especially the notorious Tuskegee Syphilis Study [14–18],
described as ‘‘the singular reason behind African-American
distrust of the institutions of medicine and public health’’
[19].
The claim that racial and ethnic minority groups in the US
are less willing to participate in health research seems to be
validated by data showing that minority groups are under-
represented in at least some health research studies [20–25].
Yet, willingness to participate is just one factor that
inﬂuences whether individual patients and patient groups
participate in health research [9,26]. Other factors include
whether they are informed of research opportunities,
whether they are medically eligible to participate, and
whether their personal circumstances, including child care
demands, job ﬂexibility, and geographic proximity to
research sites, allow them to participate.
Simply assuming that minority groups’ underrepresenta-
tion in some health studies is a result of their being less
willing to participate may focus efforts aimed at increasing
their participation on changing minority attitudes. If,
however, minorities are equally willing to participate, and
their lower participation in some studies traces to other
factors, these efforts may prove ineffective, or even counter-
productive. The assumption that minority groups are less
willing to participate in health research also may inadver-
tently increase stigmatization, suggesting that minority
groups are unwilling to bear their fair share of the burdens
required to improve medical care.
A few studies have assessed the willingness of racial and
ethnic minority groups to participate in individual research
trials and trials that focus on single diseases [7,27,28].
However, we could ﬁnd no published empirical data on the
actual consent rates of minority groups for health research in
general. To evaluate the widespread claim that racial and
ethnic minorities are less willing to participate in health
research, we assessed whether individuals from minority
groups who were eligible and invited to participate in health
research consented to enroll less frequently than non-
Hispanic whites.
Methods
Non-Intervention Studies
The Tuskegee Syphilis Study, thought to be a major reason,
particularly in the US, behind racial and ethnic minority
groups’ presumed unwillingness to participate in health
research, was a US government-funded, epidemiologic study.
To assess racial and ethnic minority groups’ willingness to
participate in current US government-funded, epidemiologic
studies, we evaluated the health surveys conducted by the US
National Center for Health Statistics (NCHS) for the most
recent year for which data were available, year 2000.
The NCHS, the nation’s principal health statistics agency,
conducts two ongoing population based health surveys—the
National Health Interview Survey (NHIS) and the National
Health and Nutrition Examination Survey (NHANES). The
NCHS, in collaboration with the National Immunization
Program, also conducts the National Immunization Survey
(NIS), which collects data that can be used to determine
consent rates by race. The other health surveys conducted by
the NCHS did not qualify for analysis, either because they are
based on the NHIS sample, or because they are based on
administrative records, not direct contact with individuals.
Thus, three survey or non-intervention studies conducted by
the NCHS that provide data on consent rates by race or
ethnicity are included in the analysis.
The NHIS is an annual, in-person, household interview,
Figure 1. Ethnic and Racial Composition of the United States
Data from year 2003.
DOI: 10.1371/journal.pmed.0030019.g001
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designed to produce data representative of the civilian, non-
institutionalized population of the US [29]. The sample
consists of approximately 106,000 persons, in approximately
43,000 households in over 300 primary sampling units. The
ﬁrst part of the survey collects basic demographic and health
data on all members of the household. A sample adult and
child are then selected from each household to complete a
more detailed interview that assesses illness, health-care
utilization, and socioeconomic and demographic factors. All
households selected into the sample are visited by inter-
viewers to introduce the study and conduct a brief interview
to determine eligibility. Data on race and ethnicity are
collected at this initial contact. The NHIS invites a higher
percentage of African-Americans and Hispanics to partic-
ipate than the percentage of these two groups in the US
population. Interview response rates were calculated for
sample adults for whom demographic information was
obtained during the initial contact. The NHIS neither
conducts public outreach nor provides ﬁnancial incentives.
The NIS is an annual, random-digit-dialing telephone
survey of approximately 34,000 US households with at least
one child 19–35 mo old [30]. After answering questions about
the resident child’s immunization status, participants are
asked for approval to contact providers to obtain the child’s
immnunization records. The NIS neither conducts public
outreach nor provides ﬁnancial incentives.
The NHANES is an annual nationally representative
sample survey of approximately 5,000 non-institutionalized
US civilians. Extensive media and public outreach are
conducted in each community to familiarize potential
participants with the survey. The household interview
component of the NHANES assesses respondents’ health,
health-care utilization, and demographic characteristics [31].
Participants do not receive any ﬁnancial incentives for the
interview portion of the NHANES.
Individuals who complete the interview portion of the
NHANES are invited to participate in an extensive medical
examination, which requires a separate consent. The medical
examination lasts approximately 4 h and includes a physical
examination and a second interview. The physical examina-
tion collects blood and urine samples for laboratory tests
such as cholesterol levels, blood lead levels, and levels of
exposure to other environmental health hazards. The inter-
view includes questions on physical health, mental health,
sexual behavior, and drug use. Participants who complete the
physical examination receive $70–$100 for their time and
effort. Because individuals must have already consented to
the NHANES interview to be invited to participate in the
medical examination, the consent rates for the medical
examination are listed (Table 1), but not included in the
overall statistical analysis.
Health Intervention Studies
Because there are no databases of health intervention
trials, we conducted a comprehensive literature search of
published trials. Using PubMed (http://www.ncbi.nlm.nih.gov/
entrez/), we searched 30 unique combinations of terms and
strings of terms related to enrollment, refusal, race, and
ethnicity in phase I trials, phase I/II trials, phase II trials, and
randomized controlled trials (see Table S1 for search terms).
Studies were eligible for inclusion if they documented the
race or ethnicity of eligible individuals invited to enroll, as
well as the race or ethnicity of those who actually enrolled.
Two authors (G. V. and C. P. G.) reviewed the titles of all
1,681 articles identiﬁed by the search terms, then retrieved
abstracts for the 1,106 articles that included any terms related
to consent rates, including ‘‘consent,’’ ‘‘eligible,’’ ‘‘refusal,’’ or
‘‘enrollment’’ (see Figure S1 for a description of the selection
process). The abstracts of all 1,106 retrieved articles were
reviewed for any terms or phrases suggesting that they might
include data by race or ethnicity, including ‘‘race,’’ ‘‘eth-
nicity,’’ ‘‘Caucasian,’’ ‘‘African-American,’’ ‘‘Hispanic,’’ and
‘‘non-Hispanic white.’’ The full texts of the 68 articles that
included any of these terms were reviewed to determine
whether they included data on consent rates by race or
ethnicity, yielding 17 unique articles.
Next, Web of Science was used to search for authors whose
names appeared in the citations of two or more of the 17
identiﬁed articles, yielding 371 articles (see Table S2). Using
the same selection process, the bibliographies of the 17
identiﬁed articles were reviewed for any articles mentioning
consent or participation rates, yielding another 89 articles.
The same two authors (G. V. and C. P. G.) repeated the
selection process to search the original 1,681 articles to
determine whether any of these additional 467 articles
included data on consent rates by race or ethnicity. This
search yielded no additional articles.
Finally, to assess whether our search missed any studies
that document consent rates by race or ethnicity, we
evaluated the articles published for an entire year for two
different types of trials. First, we reviewed all randomized
controlled trials published during the 1-y period beginning
April 1, 1999, in four major clinical journals: Annals of Internal
Medicine, JAMA, The Lancet, and The New England Journal of
Medicine. Because we wanted to assess individual patients’
willingness to enroll in health research, trials were included
only if they used individual patients as the unit of random-
ization (as opposed to hospital, region, etc.). This search
identiﬁed 172 articles. We next conducted a MedLine search
to identify all phase I oncology trials that used safety as an
endpoint, published in English in the year 2002. This search
identiﬁed 250 articles.
Using the same search process that was used for the
original 1,681 studies, all 422 so identiﬁed articles were
reviewed to determine whether any documented consent
rates by race or ethnicity. This search yielded one study that
documented consent rates by race, which had been identiﬁed
previously by our original MedLine search. The fact that this
search of the published articles for an entire year for two
different types of intervention trials did not yield any new
articles suggests that our original search likely identiﬁed all
studies published in English that documented consent rates
by race or ethnicity.
Statistical Analysis
We deﬁned the consent rates for a given study as the
number of individuals in each reported racial or ethnic group
who agreed to participate in the study divided by the number
of individuals in that group who were invited to participate.
The identiﬁed studies classiﬁed minority groups in four
different ways: (1) African-Americans and Hispanics classiﬁed
separately; (2) only African-Americans classiﬁed; 3) African-
Americans classiﬁed separately and all other minorities
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grouped together; 4) all minorities grouped together. Because
the original studies used different race/ethnic classiﬁcations,
the minority group(s) to which non-Hispanic whites are
compared in the present analysis varies across the studies.
For each study, we calculated an odds ratio (OR) and the
associated 95% conﬁdence interval (CI) using non-Hispanic
whites as the reference group. The OR speciﬁes, for each
study, whether the reported minority group was more or less
likely to consent to enrollment than non-Hispanic whites. An
OR greater than one indicates that the minority group was
more likely to consent than non-Hispanic whites; an OR of
less than one indicates that the minority group was less likely
to consent. A DerSimonian–Laird random effects model was
used to estimate the summary OR and 95% CI for each type
of study (i.e., non-intervention studies, clinical intervention
studies, and surgical intervention studies), again using non-
Hispanic whites as the reference group [32].
We considered the summary OR to be statistically
signiﬁcant if the 95% CI did not include one. We also used
the following statistic to test for statistical signiﬁcance:
X ¼ ðlnðK^Þ=s  Þ2; ð1Þ
where K^ is the estimated summary OR and s* is the estimated
standard deviation of the log summary OR. Under the null
hypothesis that K¼ 1, X has a v2 distribution with one degree
of freedom. We also tested for homogeneity by calculating a
Breslow–Day v2 statistic.
Results
We found 20 health research studies that included
sufﬁcient data to determine consent rates by race or
ethnicity. Eighteen of the twenty studies were single-site
studies conducted exclusively in the US or multi-site studies
where the majority of sites (i.e., at least 2/3) were in the US. Of
the remaining two studies, the Concorde study was conducted
at 74 sites in the United Kingdom, Ireland, and France, while
the Delta study was conducted at 152 sites in Europe and 23
sites in Australia and New Zealand. Taken together, these 20
studies reported the enrollment decisions of over 70,000
individuals, the vast majority of whom were from the US, for
a broad range of health research studies, from interviews and
non-intervention studies to drug treatment and surgical
trials.
For the three interview or non-intervention studies,
African-Americans had a nonsigniﬁcantly lower overall
consent rate than non-Hispanic whites (82.2% versus
83.5%; OR ¼ 0.92; 95% CI 0.84–1.02; Table 1; Figure 2). For
these same three studies, Hispanics had a nonsigniﬁcantly
higher overall consent rate than non-Hispanic whites (86.1%
versus 83.5%; OR ¼ 1.37; 95% CI 0.94–1.98; Figure 3).
Additionally, there was a signiﬁcant lack of homogeneity for
both comparisons (i.e., the test of homogeneity of the OR was
rejected). A lack of homogeneity indicates that the relative
willingness to enroll of minority groups versus non-Hispanic
whites was not consistent, but varied signiﬁcantly within the
group of studies.
For the ten clinical intervention studies, African-Ameri-
cans had a nonsigniﬁcantly higher overall consent rate than
non-Hispanic whites (45.3% versus 41.8%; OR¼ 1.06; 95% CI
0.78–1.45; Table 2; Figure 2). Again, there was a signiﬁcant
lack of homogeneity among the ORs, indicating that the
relative willingness to enroll of minority groups versus non-
Hispanic whites varied signiﬁcantly within the group of
studies. For these same ten studies, Hispanics had a statisti-
cally signiﬁcant higher overall consent rate than non-
Hispanic whites (55.9% versus 41.8%; OR ¼ 1.33; 95% CI
1.08–1.65; Figure 3).
Table 3 reports the consent rates for the seven surgical
intervention studies, which categorized all minority groups
together. For these seven trials, minorities as a group had a
nonsigniﬁcantly higher overall consent rate than non-
Hispanic whites (65.8% versus 47.8%; OR ¼ 1.26; 95% CI
0.89–1.77; Figure 4). While the test of homogeneity was only
nominally signiﬁcant (p ¼ 0.046), six of the seven ORs were
greater than one.
Importantly, of the 20 studies identiﬁed, seven offered
enrollment to very few minority individuals. For example, the
BARI study of percutaneous transluminal coronary angio-
plasty versus coronary artery bypass graft for coronary artery
disease offered enrollment to 3,832 non-Hispanic whites, but
to only 16 individuals from all minority groups combined
Table 1. Interviews and Non-Intervention Studies
Trial Name and
Date Published
Trial Type Non-Hispanic White African-American Hispanic
Offered
Enrollment
Consent
Rate
Offered
Enrollment
Consent
Rate
OR
(95% CI)a
Offered
Enrollment
Consent
Rate
OR
(95% CI)b
NHIS 2000 In-person interview 25,515 83.6% 5,622 81.1% 0.84 (0.78–0.91) 6,584 81.7% 0.88 (0.82–0.94)
NHANES 2000 In-person interview 1,778 79.0% 897 78.5% 0.97 (0.80–1.18) 1,207 86.0% 1.63 (1.34–1.99)
NIS 2000 Review of child’s
medical chart
19,420 83.8% 6,095 83.7% 1.00 (0.92–1.08) 6,706 90.4% 1.82 (1.67–2.00)
Summaryc 46,713 83.5% 12,614 82.2% 0.92 (0.84–1.02)d 14,497 86.1% 1.37 (0.94–1.98)e
NHANES 2000 4-h medical exam 1,778 74.9% 897 75.7% 1.04 (0.86–1.26) 1,207 82.4% 1.56 (1.30–1.87)
Consent rates for the NIS chart review are by race of the mother, the most frequent consenter.
aComparing the consent rate of African-Americans to the consent rate of non-Hispanic whites. Test of homogeneity: p ¼ 0.01.
bComparing the consent rate of Hispanics to the consent rate of non-Hispanic whites. Test of homogeneity: p-value , 0.001.
cThe summary statistics do not include the NHANES 4-h medical exam.
dp ¼ 0.11 (v2 test from random effects model).
ep ¼ 0.098 (v2 test from random effects model).
DOI: 10.1371/journal.pmed.0030019.t001
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(Table 3). Similarly, the CASS study of surgery versus medical
management for angina pectoris offered enrollment to 2,065
non-Hispanic whites, but to only 30 individuals from all
minority groups (Table 3).
Discussion
We identiﬁed 20 health research studies that reported the
consent rates by race or ethnicity of over 70,000 individuals,
the vast majority of whom were from the US. These 20 studies
reveal small differences in the rates at which non-Hispanic
whites and minorities agree to participate in health research.
Indeed, where there are differences in consent rates,
individuals from minority groups tend to be slightly more
willing to participate in health research, particularly for
clinical and surgical intervention studies. These ﬁndings
contradict the widely held view that racial and ethnic
Figure 2. Comparison of African-American versus non-Hispanic White Consent Rates
Circle diameter is proportional to the sample size of the individual studies. The diamond represents the overall OR. The vertical line indicates the 95%
confidence interval on the OR. Blue indicates interview and non-intervention studies; red indicates clinical intervention studies.
DOI: 10.1371/journal.pmed.0030019.g002
Figure 3. Comparison of Hispanic versus non-Hispanic White Consent Rates
Circle diameter is proportional to the sample size of the individual studies. The diamond represents the overall OR. The vertical line indicates the 95%
confidence interval on the OR. Blue indicates interview and non-intervention studies; red indicates clinical intervention studies.
DOI: 10.1371/journal.pmed.0030019.g003
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minority groups in the US are less willing than non-Hispanic
whites to participate in health research.
Our ﬁndings are striking given that they represent the
enrollment decisions of over 70,000 individuals, including
over 14,000 individuals who were invited to participate in
clinical and surgical intervention trials. Furthermore,
although we found only 20 studies that reported consent
rates by race or ethnicity, these studies represent a broad
Table 2. Clinical Intervention Trials
Trial Name and
Date Published
Trial Type
(Disease)
Non-Hispanic White African-American Hispanic
Offered
Enrollment
Consent
Rate
Offered
Enrollment
Consent
Rate
OR
(95% CI)a
Offered
Enrollment
Consent
Rate
OR
(95% CI)b
Robinson 1994 [50] Drug maintenance
(schizophrenia)
611 37.2% 521 49.1% 1.63 (1.29–2.07) 94 47.9%c 1.55 (1.01–2.40)
McKay 1995 [51] Day hospital vs. inpatient
(substance abuse)
45 20.0% 96 39.6% 2.53 (1.11–5.75) n/a n/a n/a
CAST 1996 [52] Drug trial
(cardiac arrhythmia)
1,249 16.4% 251 15.5% 0.94 (0.65–1.37) 76 18.4% 1.18 (0.65–2.13)
Rimer 1996 [53] Risk counseling
(breast cancer)
673 60.0% 178 43.3% 0.51 (0.36–0.71) n/a n/a n/a
WEST 1996 [54] Estrogen treatment
(cardiovascular disease)
667 34.6% 97 34.0% 0.98 (0.63–1.53) 25 40.0% 1.28 (0.57–2.84)
MBCOOP 1997 [55] Drug trial
(cancer)
251 62.2% 404 60.4% 0.93 (0.67–1.28) 151 70.2% 1.43 (0.93–2.20)
Concorde 2000 [56] Drug trial
(HIV infection)
236 70.3% 25 64.0% 0.74 (0.32–1.71) n/a n/a n/a
Delta 2000 [56] Drug trial
(HIV infection)
169 71.6% 17 88.2% 2.47 (0.62–9.81) n/a n/a n/a
Westerberg 2000 [57] Treatment trial
(alcohol abuse)
167 62.9% n/a n/a n/a 181 66.9% 1.19 (0.77–1.85)
COMS 2001 [58] Radiation
(ocular melanoma)
2,823 45.7% 15 53.3 1.35 (0.50–3.61) 28 50.0% 1.19 (0.57–2.47)
Summary 6,724 41.8% 1,604 45.3% 1.06 (0.78–1.45)d 555 55.9% 1.33 (1.08–1.65)e
aComparing the consent rate of African-Americans to the consent rate of non-Hispanic whites. Test of homogeneity: p , 0.001.
bComparing the consent rate of Hispanics to the consent rate of non-Hispanic whites. Test of homogeneity: p ¼ 0.95.
cFor the Robinson study, the consent rate reported in the Hispanic category is for all minorities, with the exception of African-Americans, grouped together.
dp ¼ 0.69 (v2 test).
e p ¼ 0.011 (v2 test); with the Robinson study removed from the analysis, the OR is 1.27 and the 95% CI is 0.99–1.62.
n/a, data not reported in the original study.
DOI: 10.1371/journal.pmed.0030019.t002
Table 3. Surgical Intervention Trials
Trial Name and
Date Published
Trial Type
(Disease)
Non-Hispanic White All Minority Groups
Offered
Enrollment
Consent
Rate
Offered
Enrollment
Consent
Rate
OR
(95% CI)
CASS 1984 [59] Surgery vs. medical management
(angina pectoris)
2,065 37.1% 30 43.3% 1.31 (0.64–2.67)
Paradise 1984 [60] Tonsillectomy vs.tonsillectomy with adenoidectomy
(recurrent throat infection)
172 47.1% 15 66.7%a 2.14 (0.73–6.27)
Williford 1993 [61] TPN (post-surgery malnourishment) 432 63.7% 162 74.1% 1.62 (1.09–2.42)
Marcus 1997 [62] Surgery vs. medical management
(recurrent otitis media)
175 50.9% 37 27.0% 0.37 (0.17–0.80)
EAST 1997 [63] PTCA vs. CABG
(coronary artery disease)
793 46.3% 49 51.0% 1.21 (0.68–2.14)
SHOCK 1999 [64] Surgery vs. medical management
(myocardial infarction with shock)
296 77.0% 89 83.1% 1.44 (0.78–2.65)
BARI 2000 [65] PTCA vs. CABG (coronary artery disease) 3,823 47.6% 16 62.5% 1.78 (0.67–4.74)
Summary 7,756 47.8% 398 65.8% 1.26 (0.89–1.77)b
a For the Paradise study, the consent rate reported for ‘‘all minority groups’’ is for African-Americans only.
b p ¼ 0.19 (v2 test); with the Paradise study removed, the OR is 1.20 and the 95% CI interval is 0.83–1.72; test of homogeneity: p-value¼ 0.046.
CABG, coronary artery bypass graft; PTCA, percutaneous transluminal coronary angioplasty; TPN, total parenteral nutrition.
DOI: 10.1371/journal.pmed.0030019.t003
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range of invasiveness and risk, from in-person interviews and
medical chart reviews, to drug treatment and surgical trials.
These studies also cover a broad range of conditions,
including recurrent throat infection, substance abuse, schiz-
ophrenia, HIV infection, cancer, and cardiac diseases.
Studies suggest that various factors, including historic
abuses like the Tuskegee study, may have undermined
minority groups’ trust in medical research, as measured by
survey questions and focus groups [33,34]. These factors may
have increased individuals’ suspicions or decreased their level
of trust. However, the present analysis reveals that these
factors have not resulted in racial and ethnic minorities in
the US being less willing to participate in health research [35].
Although we found only small differences in consent rates
by race or ethnicity, we did ﬁnd substantial differences by
race and ethnicity in the number of individuals invited to
participate. In particular, seven of the 17 clinical and surgical
intervention studies offered enrollment to relatively few
individuals from minority groups, substantially fewer than
one would expect based on the percentage of the population
composed of minority groups and the incidence of the
diseases being studied. For instance, the CASS study of
surgery versus medical management for angina pectoris
offered enrollment to a total of 2,095 individuals, 2,065 of
whom were non-Hispanic whites and only 30 of whom were
from all minority groups combined. Yet, as of 1980, 17% of
the U.S. population belonged to a minority group, and the
estimated prevalence of angina pectoris is higher in minority
groups, especially African-Americans and Hispanics, than in
non-Hispanic whites [36]. Recognizing that this rough
estimate of minority representation in the US fails to take
into account other relevant considerations, US demographics
and the prevalence of angina pectoris suggest that the CASS
study, which recruited individuals in the late 1970s, should
have offered enrollment to approximately 356 individuals
from minority groups (17% of 2,095), more than ten times the
30 individuals from minority groups actually offered enroll-
ment [37].
Looking at the number of individuals who participated,
one might conclude that these studies support the thesis that
minorities are less willing to participate in health research in
the US. This conclusion is contradicted by the studies’ actual
consent rates. In the BARI study, individuals from minority
groups agreed to participate at a signiﬁcantly higher rate
than non-Hispanic whites (62.5% versus 47.6%). Similarly,
individuals from minority groups agreed to participate at a
signiﬁcantly higher rate than non-Hispanic whites in the
CASS study (43.3% versus 37.1%).
We found a signiﬁcant lack of homogeneity for all pooled
statistics, with the exception of Hispanics’ and non-Hispanic
whites’ comparative willingness to enroll in clinical inter-
vention trials. This lack of homogeneity indicates that the
relative willingness to enroll of minority groups versus non-
Hispanic whites varies signiﬁcantly within the various groups
of studies.
The lack of homogeneity suggests that comparative
willingness to enroll in speciﬁc studies cannot be inferred
simply from the type of study, or the racial or ethnic groups
in question. Instead, it appears that individuals from
minority groups are more willing to enroll in some studies,
and non-Hispanic whites are more willing to enroll in
others. This ﬁnding suggests that willingness to enroll often
is more a function of the characteristics of individual studies
than a function of racial or ethnic identity. Hence, in cases
where a study has difﬁculty enrolling individuals from a
particular group, whether a minority group or non-Hispanic
whites, it will be important to assess whether particular
characteristics of the study account for this difference. For
example, choice of study site may have an important impact
on which groups are likely to enroll. Also, the lack of
Figure 4. Comparison of Minority versus non-Hispanic White Consent Rates in Surgical Intervention Trials
Circle diameter is proportional to the sample size of the individual studies. The diamond represents the overall OR. The vertical line indicates the 95%
confidence interval on the OR.
DOI: 10.1371/journal.pmed.0030019.g004
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homogeneity suggests that it may be important to conduct
further research to determine which characteristics of
studies inﬂuence the willingness of racial and ethnic groups
to participate.
Numerous writers have emphasized the need to increase
minority participation in health research [38–42]. Such
efforts are important for reasons of justice, and to ensure
research ﬁndings are generalizable to the entire population.
These efforts are especially important given data that
minority groups are not represented adequately in some
clinical trials [1–4,25]. If efforts to increase minority
participation are to succeed, it is vital to understand why
minority groups are underrepresented in some research
trials. Widespread discussion of past abuses, and racial and
ethnic minorities’ presumed unwillingness to participate, has
focused attention on the attitudes of individuals from
minority groups. However, the current data suggest individ-
uals from minority groups, at least in the US, are as willing as
non-Hispanic whites to participate in health research when
eligible and invited to participate.
This ﬁnding suggests that any underrepresentation of
minority groups in health research, when it occurs, is likely
the result of other factors, such as the fact that some studies
invite comparatively few individuals from minority groups to
participate [43]. Consequently, efforts to increase minority
participation in health research should focus on increasing
minority access to research participation, not changing
minority attitudes [44–47]. To be successful, these efforts
should take into account a number of considerations [48].
Informing minority groups of speciﬁc trials and inviting them
to participate is an obvious step. In addition, health research
trials should try to include sites that are accessible to minority
groups, and identify and attempt to address factors that may
undermine minority groups’ participation in particular, such
as the need for child care and reimbursement for travel
expenses. Language barriers also may pose difﬁculties with
recruiting some minority groups [49].
Several limitations suggest the need for future research.
First, the current ﬁndings are limited to published articles
that documented consent rates by race or ethnicity. Second,
the vast majority of the over 70,000 individuals in the present
analysis were from the US. The willingness of minority groups
from other countries to participate in health research may
differ from the willingness of minority groups in the US. For
example, time and cost constraints may preferentially reduce
the willingness of individuals from minority groups to
participate in health research in general. Yet, this factor
may be outweighed in the US by the fact that health care is
not guaranteed, and individuals from minority groups may be
more likely to use participation in research as a way to obtain
access to physicians and health care.
Third, we did not assess minority groups’ attitudes toward
health research. The current ﬁndings do not rule out the
possibility that past abuses have resulted in individuals from
minority groups being more distrustful of health research
than non-Hispanic whites. It may be that past abuses have led
to greater distrust among minority groups, but that other
factors result in individuals from minority groups being
equally willing to participate overall. For instance, some
minority groups are more likely to be from lower socio-
economic groups, and individuals from lower socioeconomic
groups may be comparatively more willing to participate in
research for a number of possible reasons, including a
stronger sense of social obligation or to gain access to health
treatments.
Fourth, our comprehensive search focused on clinical
intervention trials, speciﬁcally phase I, phase I/II, phase II,
and randomized controlled trials. Our search did not include
prevention trials and natural history studies. Individuals from
minority groups may be less willing than non-Hispanic whites
to participate in these types of studies.
It is widely believed that racial and ethnic minorities are
less willing to participate in health research. Such claims
often focus on the US, where it is believed that minority
groups’ relative unwillingness to participate in health
research traces to historic abuses, especially the notorious
Tuskegee Syphilis Study. We found that racial and ethnic
minorities in the US, particularly African-Americans and
Hispanics, are as willing to participate, and in some instances
more willing to participate, in health research than non-
Hispanic whites, when eligible and invited to participate.
These ﬁndings suggest that efforts to remedy any under-
representation of minority groups in health research should
focus on ensuring equal access to health research for all
groups, not on changing attitudes. Efforts to increase
minority groups’ access to clinical research studies should
focus on a range of considerations, including inviting
minority groups to participate, using sites accessible to
minority groups, and identifying and attempting to address
factors that may undermine the participation of individuals
from minority groups, such as the need for child care or
reimbursement of travel expenses.
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Patient Summary
Background. Health research is meant to determine the best strategies
for preventing and treating disease and to inform health policy. Approval
of new drugs and health guidelines is usually issued at a national level.
Many countries have ethnically and racially diverse populations, and we
know that health parameters are not the same for the different groups.
To make sure that health policies serve a diverse population, it is
important that all ethnic and racial groups participate in health research.
Why Was This Study Done? Several studies have found that minority
groups, especially in the US, are often underrepresented in research
studies. One possible explanation that has been suggested is that
because of past abuses (especially of African-Americans in the notorious
Tuskegee Syphilis Study), minorities are less willing to participate in
medical research. The authors of this study wanted to test whether this
was indeed the case.
What Did the Researchers Do and Find? They looked through the
health literature in a systematic way to find all recent studies that
reported consent rates by race or ethnicity (every participant in health
research has to give ‘‘informed consent’’). They found 20 such studies, 18
of which were conducted primarily or exclusively in the US, covering a
broad range of research from interview-based surveys to clinical trials.
Taken together, these studies reported the decision of over 70,000
individuals who were invited to participate. The researchers then
compared the consent rates (i.e., the proportion who actually agreed
to participate and gave consent) among non-Hispanic whites, African-
Americans, and Hispanics. They found very small differences in the
overall willingness of minorities to participate in health research
compared with non-Hispanic whites. However, they did find that many
of the studies invited fewer minority individuals than would be
representative for the US patient population.
What Does This Mean? These results suggest that racial and ethnic
minority groups, at least in the US, are as willing as non-minority
individuals to participate in health research, but that they are
underrepresented among the invited participants. Efforts to increase
minority participation should therefore focus on offering participation to
more minority individuals rather than focusing on changing minority
attitudes. It will be important to determine why minorities are
underrepresented among people invited to participate in health
research. Another interesting question not answered by this study is
what motivates individuals from the different groups to accept an
invitation and participate in health research both in general and in a
particular survey or trial.
Where Can I Find More Information Online? Information on the
Tuskeege study:
http://www.cdc.gov/nchstp/od/tuskegee/
http://www.pbs.org/newshour/bb/health/may97/tuskegee_5–16.html
http://www.npr.org/programs/morning/features/2002/jul/tuskegee/
commentary.html
Office of Minority Health Affairs of the US National Heart, Lung, and
Blood Institute:
http://www.nhlbi.nih.gov/about/omha/
Pages on minority resources and initiatives at the US National Human
Genome Research Institute:
http://www.genome.gov/10011199
Report on Inclusion of Women and Minorities in Research from the Office
for Protection from Research Risks:
http://www.hhs.gov/ohrp/humansubjects/guidance/hsdc94–01.htm
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